Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$304.2 M
Burn Rate (Qtr)
$54.4M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q1 '22
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
ADAP
Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Recent Posts
See what the community is saying - click to see full post.